PDF(Pubmed)
Abstract：
UNASSIGNED: Radial artery occlusion (RAO) remains the most frequent complication of trans-radial access. Once the radial artery is occluded, its future use as an access site for coronary procedures, or as a conduit for coronary bypass grafting or fistula for hemodialysis, will be precluded. Therefore, we aimed to assess the value of the short-term use of Rivaroxaban to prevent RAO after a trans-radial coronary procedure.
UNASSIGNED: This was a prospective, open-label, randomized study. The patients were randomly assigned (1:1) to one of two groups: those who received Rivaroxaban 10 mg for 7 days following the trans-radial coronary procedure (the Rivaroxaban Group) and those who received the standard treatment (the Control Group). The primary outcome was an occurrence of RAO evaluated by Doppler ultrasound at 30 days, and the secondary outcomes were hemorrhagic complications according to BARC classification.
UNASSIGNED: We included 521 patients randomized into two Groups: the Control Group (N = 262) and the Rivaroxaban Group (N = 259). The 1-month RAO was significantly reduced in the Rivaroxaban Group as compared to the Control Group [6.9% vs. 13%; p = 0.011, OR = 0.5, (95% CI, 0.27-0.91)]. We noted no cases of severe bleeding events (BARC3-5). The overall incidence of minor bleeding (BARC1) was 2.3%, with no significant difference between the two groups [Rivaroxaban Group = 2.7%, Control Group = 1.9%, p = 0.54, OR= 1.4, (95%CI 0.44-4.5)].
UNASSIGNED: Short-term postoperative anticoagulation with Rivaroxaban 10 mg for seven days reduces the rate of 1-month RAO.
UNASSIGNED: This was a prospective, open-label, randomized study. The patients were randomly assigned (1:1) to one of two groups: those who received Rivaroxaban 10 mg for 7 days following the trans-radial coronary procedure (the Rivaroxaban Group) and those who received the standard treatment (the Control Group). The primary outcome was an occurrence of RAO evaluated by Doppler ultrasound at 30 days, and the secondary outcomes were hemorrhagic complications according to BARC classification.
UNASSIGNED: We included 521 patients randomized into two Groups: the Control Group (N = 262) and the Rivaroxaban Group (N = 259). The 1-month RAO was significantly reduced in the Rivaroxaban Group as compared to the Control Group [6.9% vs. 13%; p = 0.011, OR = 0.5, (95% CI, 0.27-0.91)]. We noted no cases of severe bleeding events (BARC3-5). The overall incidence of minor bleeding (BARC1) was 2.3%, with no significant difference between the two groups [Rivaroxaban Group = 2.7%, Control Group = 1.9%, p = 0.54, OR= 1.4, (95%CI 0.44-4.5)].
UNASSIGNED: Short-term postoperative anticoagulation with Rivaroxaban 10 mg for seven days reduces the rate of 1-month RAO.
摘要：
■桡动脉闭塞（RAO）仍然是经桡动脉途径最常见的并发症。一旦桡动脉闭塞,它未来用作冠状动脉手术的进入部位，或者作为冠状动脉旁路移植术或血液透析用瘘的导管，将被排除在外。因此,我们旨在评估经桡动脉冠状动脉手术后短期使用利伐沙班预防RAO的价值.
■这是一个前景，开放标签，随机研究。将患者随机分为（1：1）两组：经桡动脉冠状动脉手术后接受利伐沙班10mg持续7天的患者（利伐沙班组）和接受标准治疗的患者（对照组）。主要结果是在30天通过多普勒超声评估RAO的发生，次要结局是根据BARC分类的出血性并发症.
■我们将521例患者随机分为两组：对照组（N=262）和利伐沙班组（N=259）。与对照组相比，利伐沙班组的1个月RAO显着降低[6.9％vs.13%；p=0.011，OR=0.5，(95%CI，0.27-0.91)]。我们注意到没有严重出血事件（BARC3-5）。轻微出血（BARC1）的总发生率为2.3％，两组之间没有显着差异[利伐沙班组=2.7％，对照组=1.9%，p=0.54，OR=1.4，（95CI0.44-4.5）]。
■术后短期使用利伐沙班10mg抗凝治疗7天，可降低1个月RAO的发生率。
■这是一个前景，开放标签，随机研究。将患者随机分为（1：1）两组：经桡动脉冠状动脉手术后接受利伐沙班10mg持续7天的患者（利伐沙班组）和接受标准治疗的患者（对照组）。主要结果是在30天通过多普勒超声评估RAO的发生，次要结局是根据BARC分类的出血性并发症.
■我们将521例患者随机分为两组：对照组（N=262）和利伐沙班组（N=259）。与对照组相比，利伐沙班组的1个月RAO显着降低[6.9％vs.13%；p=0.011，OR=0.5，(95%CI，0.27-0.91)]。我们注意到没有严重出血事件（BARC3-5）。轻微出血（BARC1）的总发生率为2.3％，两组之间没有显着差异[利伐沙班组=2.7％，对照组=1.9%，p=0.54，OR=1.4，（95CI0.44-4.5）]。
■术后短期使用利伐沙班10mg抗凝治疗7天，可降低1个月RAO的发生率。
